翰森制药HS-10365胶囊上市许可申请获国家药监局受理

Core Viewpoint - Hansoh Pharmaceutical (03692.HK) has received acceptance from the National Medical Products Administration for its New Drug Application (NDA) for HS-10365 capsules, a selective RET inhibitor aimed at treating adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with RET gene fusion [1] Group 1: Product Development - HS-10365 is a first-class innovative drug developed by Hansoh Pharmaceutical [1] - It is a small molecule, highly selective RET receptor tyrosine kinase inhibitor [1] - The drug works by competitively binding to intracellular protein tyrosine kinases with ATP, inhibiting tyrosine kinase phosphorylation, and effectively controlling tumor growth [1]